What are optimal glycemic targets associated with reduced dementia risk in older people with type 2 diabetes?

Written By :  Dr. Krishna Shah
Medically Reviewed By :  Dr. Kamal Kant Kohli
Published On 2023-05-10 04:00 GMT   |   Update On 2023-05-10 09:25 GMT

The risk for dementia is found to be the greatest among elderly type 2 diabetic people who had cumulative HbA1c concentrations of 9% or more, suggests a study from Australia recently published in JAMA Neurology.Although type 2 diabetes is associated with increased dementia risk, it is unclear whether glycemic control mediates this risk in people in middle to later life. Observational studies...

Login or Register to read the full article

The risk for dementia is found to be the greatest among elderly type 2 diabetic people who had cumulative HbA1c concentrations of 9% or more, suggests a study from Australia recently published in JAMA Neurology.

Although type 2 diabetes is associated with increased dementia risk, it is unclear whether glycemic control mediates this risk in people in middle to later life. Observational studies have reported that hyperglycemia and duration of diabetes are associated with increased dementia risk. However, studies of interventions with aggressive glycemic targets suggest that attempting to achieve strict glycemic control may increase the risk of harm, including death, particularly in older patients.

The harm associated with intensive glucose control has led the American Diabetes Association, American Geriatrics Society, Endocrine Society, and US Department of Veterans Affairs to recommend that glycemic targets for people in middle to later life be individualized and to consider risk of hypoglycemia, number and severity of comorbidities, functional independence, cognitive impairment, and life expectancy. Each of these organisations differs with regard to the exact therapeutic target recommended and encourages this to be developed based on a person’s individual circumstances.

To help inform patient-centered glycemic target setting, it is essential to understand the contribution of glycemic control to dementia risk. Long-term glycemic control, measured using cumulative glycemic exposure via multiple glycated hemoglobin (HbA1c) measurements over time, provides a more nuanced understanding of glycemic control than mean HbA1c concentrations.

Moran et al in their study aimed to examine the associations between cumulative exposure to various ranges of HbA1c with dementia risk across sex and racial and ethnic groups and explore the association of current therapeutic glycemic targets with dementia risk.

The authors found that greater cumulative exposure to HbA1c concentrations in the range of 6% to less than 7% and 7% to less than 8% was associated with lower hazard of dementia. Importantly, they observed no significant change in hazard for individuals with HbA1c concentrations in the range of relaxed glycemic control recommended by the American Geriatrics Society and US Department of Veterans Affairs for older patients with multiple comorbidities, poor health, or limited life expectancy. Although there were subtle sex and race and ethnicity differences in the dementia hazard associated with cumulative exposure to increasing HbA1c concentrations, greater time spent in commonly recommended glycemic targets was associated with lower dementia hazard across all sexes and racial and ethnic groups.

“In this cohort study of a large sample of older people with type 2 diabetes, we found that increased exposure to HbA1c concentrations greater than or equal to 9% was associated with the greatest hazard of dementia. Additional work is needed to examine whether the observational associations we report are causal and are seen in other groups”, conclude the authors.

Reference

Moran C, Lacy ME, Whitmer RA, et al. Glycemic Control Over Multiple Decades and Dementia Risk in People With Type 2 Diabetes. JAMA Neurol. Published online April 17, 2023. doi:10.1001/jamaneurol.2023.0697

Tags:    
Article Source : JAMA Neurology

Disclaimer: This site is primarily intended for healthcare professionals. Any content/information on this website does not replace the advice of medical and/or health professionals and should not be construed as medical/diagnostic advice/endorsement/treatment or prescription. Use of this site is subject to our terms of use, privacy policy, advertisement policy. © 2024 Minerva Medical Treatment Pvt Ltd

Our comments section is governed by our Comments Policy . By posting comments at Medical Dialogues you automatically agree with our Comments Policy , Terms And Conditions and Privacy Policy .

Similar News